Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Trial of the Combination of Ibrutinib and Azacitidine for the Treatment of Higher Risk Myelodysplastic Syndromes in Previously Treated Patients or in Untreated Patients Unfit for or Who Refuse Intense Therapy

NCT02553941 is registered in ClinicalTrials.gov with Brian Jonas as lead sponsor.

NCT NCT02553941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02553941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Trial of the Combination of Ibrutinib and Azacitidine for the Treatment of Higher Risk Myelodysplastic Syndromes in Previously Treated Patients or in Untreated Patients Unfit for or Who Refuse Intense Therapy
Lead sponsor
Brian Jonas
Phase
Phase 1
Overall status
Completed
Start date
May 17, 2016
Completion date
November 7, 2019
Enrollment
21 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelomonocytic leukemia, de novo myelodysplastic syndrome, previously treated myelodysplastic syndrome, refractory anemia with excess blasts in transformation, secondary myelodysplastic syndrome